Dongwha Pharm.Co.,Ltd (KRX:000020)
South Korea
· Delayed Price · Currency is KRW 6,550.00
+50.00 (0.77%)
At close: Jun 5, 2025, 3:30 PM KST
Dongwha Pharm.Co.,Ltd Revenue
Dongwha Pharm.Co.,Ltd had revenue of 125.67B KRW in the quarter ending March 31, 2025, with 5.71% growth. This brings the company's revenue in the last twelve months to 471.66B, up 23.93% year-over-year. In the year 2024, Dongwha Pharm.Co.,Ltd had annual revenue of 464.87B with 28.74% growth.
Revenue (ttm)
471.66B
Revenue Growth
+23.93%
P/S Ratio
0.38
Revenue / Employee
578.02M
Employees
816
Market Cap
181.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 464.87B | 103.77B | 28.74% |
| Dec 31, 2023 | 361.11B | 20.68B | 6.08% |
| Dec 31, 2022 | 340.43B | 47.41B | 16.18% |
| Dec 31, 2021 | 293.02B | 20.94B | 7.70% |
| Dec 31, 2020 | 272.08B | -35.07B | -11.42% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| HLB Co., Ltd. | 74.64B |
| PharmaResearch | 392.31B |
| LigaChem Biosciences | 146.42B |